KRW 2565.0
(0.79%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -21.34 Billion KRW | 12.17% |
2022 | -24.44 Billion KRW | -19.96% |
2021 | -20.37 Billion KRW | 41.21% |
2020 | -34.66 Billion KRW | 40.74% |
2019 | -58.49 Billion KRW | 1.33% |
2018 | -59.27 Billion KRW | -17.11% |
2017 | -50.61 Billion KRW | -8.1% |
2016 | -46.82 Billion KRW | -96.95% |
2015 | -23.77 Billion KRW | -56.62% |
2014 | -15.18 Billion KRW | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -4.98 Billion KRW | 18.14% |
2024 Q2 | -6.63 Billion KRW | -28.31% |
2023 Q3 | -5.64 Billion KRW | -0.67% |
2023 FY | -21.47 Billion KRW | 12.17% |
2023 Q4 | -6.09 Billion KRW | -7.95% |
2023 Q1 | -3.93 Billion KRW | 53.32% |
2023 Q2 | -5.6 Billion KRW | -42.38% |
2022 Q2 | -4.68 Billion KRW | 13.99% |
2022 FY | -24.44 Billion KRW | -19.96% |
2022 Q1 | -5.45 Billion KRW | 25.18% |
2022 Q4 | -8.43 Billion KRW | -43.5% |
2022 Q3 | -5.87 Billion KRW | -25.32% |
2021 Q2 | -4.35 Billion KRW | -4.73% |
2021 Q4 | -7.28 Billion KRW | -58.89% |
2021 FY | -20.37 Billion KRW | 41.21% |
2021 Q1 | -4.15 Billion KRW | -5.3% |
2021 Q3 | -4.58 Billion KRW | -5.37% |
2020 FY | -34.66 Billion KRW | 40.74% |
2020 Q4 | -3.94 Billion KRW | 51.04% |
2020 Q3 | -8.06 Billion KRW | 33.36% |
2020 Q2 | -12.09 Billion KRW | -14.56% |
2020 Q1 | -10.55 Billion KRW | 30.15% |
2019 Q3 | -16.87 Billion KRW | -54.84% |
2019 Q1 | -15.61 Billion KRW | -27.91% |
2019 FY | -58.49 Billion KRW | 1.33% |
2019 Q4 | -15.11 Billion KRW | 10.4% |
2019 Q2 | -10.89 Billion KRW | 30.2% |
2018 Q2 | -15.41 Billion KRW | -4.82% |
2018 Q4 | -12.2 Billion KRW | 28.01% |
2018 Q3 | -16.95 Billion KRW | -9.97% |
2018 FY | -59.27 Billion KRW | -17.11% |
2018 Q1 | -14.7 Billion KRW | -9.31% |
2017 Q2 | -16.99 Billion KRW | -66.2% |
2017 FY | -50.61 Billion KRW | -8.1% |
2017 Q1 | -10.22 Billion KRW | 38.11% |
2017 Q4 | -13.45 Billion KRW | -35.4% |
2017 Q3 | -9.93 Billion KRW | 41.55% |
2016 Q4 | -16.52 Billion KRW | -43.64% |
2016 Q2 | -10.84 Billion KRW | -36.57% |
2016 Q1 | -7.94 Billion KRW | -19.43% |
2016 FY | -46.82 Billion KRW | -96.95% |
2016 Q3 | -11.5 Billion KRW | -6.03% |
2015 Q3 | -7.13 Billion KRW | -38.04% |
2015 Q4 | -6.65 Billion KRW | 6.73% |
2015 Q2 | -5.16 Billion KRW | -7.11% |
2015 Q1 | -4.82 Billion KRW | 2.43% |
2015 FY | -23.77 Billion KRW | -56.62% |
2014 FY | -15.18 Billion KRW | 0.0% |
2014 Q2 | -4.1 Billion KRW | -102.73% |
2014 Q3 | -4.1 Billion KRW | 0.02% |
2014 Q4 | -4.94 Billion KRW | -20.44% |
2014 Q1 | -2.02 Billion KRW | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
HLB Co., Ltd. | -125.02 Billion KRW | 82.927% |
iNtRON Biotechnology, Inc. | -3.28 Billion KRW | -549.806% |
BINEX Co., Ltd. | 1.04 Billion KRW | 2148.029% |
Bioneer Corporation | 791.75 Million KRW | 2796.025% |
Anterogen.Co.,Ltd. | -5.07 Billion KRW | -320.704% |
MEDIPOST Co., Ltd. | -25.13 Billion KRW | 15.061% |
CrystalGenomics, Inc. | -30.91 Billion KRW | 30.949% |
Helixmith Co., Ltd | -35.24 Billion KRW | 39.437% |
Chabiotech Co.,Ltd. | -9.42 Billion KRW | -126.477% |
Medy-Tox Inc. | 17.32 Billion KRW | 223.227% |
Peptron, Inc. | -15.6 Billion KRW | -36.807% |
Amicogen, Inc. | 2.05 Billion KRW | 1138.151% |
Genexine, Inc. | -41.24 Billion KRW | 48.241% |
HLB Therapeutics Co.,Ltd. | -8.7 Billion KRW | -145.347% |
LegoChem Biosciences, Inc. | -80.82 Billion KRW | 73.589% |
ALTEOGEN Inc. | -9.73 Billion KRW | -119.228% |
PharmaResearch Co., Ltd. | 100.81 Billion KRW | 121.173% |
JETEMA, Co., Ltd. | 2.63 Billion KRW | 910.508% |
OliX Pharmaceuticals,Inc | -18.18 Billion KRW | -17.379% |
Genomictree Inc. | -17.3 Billion KRW | -23.362% |
MedPacto, Inc. | -28.75 Billion KRW | 25.759% |
D&D Pharmatech | -13.48 Billion KRW | -58.279% |
EASY BIO,Inc. | 20.63 Billion KRW | 203.464% |
GI Innovation, Inc. | -55.6 Billion KRW | 61.611% |